PMID- 35844014
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20230321
IS  - 1432-5195 (Electronic)
IS  - 0341-2695 (Print)
IS  - 0341-2695 (Linking)
VI  - 46
IP  - 10
DP  - 2022 Oct
TI  - The rate of venous thromboembolism after knee bone marrow concentrate procedures: 
      should we anticoagulate?
PG  - 2213-2218
LID - 10.1007/s00264-022-05500-3 [doi]
AB  - PURPOSE: Intra-articular injections of autologous, minimally manipulated, cell 
      therapies such as bone marrow concentrate (BMC) to treat knee osteoarthritis (OA) 
      may delay or prevent future total knee arthroplasty (TKA). Arthroplasty has the 
      known and substantial risk of venous thromboembolism (VTE) and requires routine 
      prophylaxis, whereas the VTE risk associated with knee BMC injections is unknown. 
      We report on the rate of VTE from a large orthobiologics patient registry and 
      assess whether knee BMC procedures require routine prophylaxis. METHODS: A 
      retrospective analysis of knee osteoarthritis cases tracked in a treatment 
      registry and treated at 72 clinical sites with BMC from 2007 to 2020 who were not 
      prophylactically anticoagulated was performed to identify adverse events (AEs) 
      associated with VTE. Treating physicians were contacted to improve discovery of 
      possible occurrences of VTE. RESULTS: Twenty cases (0.16%) of VTE were identified 
      from the registry of 12,780 knee BMC treatments. These events were less frequent 
      than the published data demonstrate for anticoagulated TKA patients. CONCLUSION: 
      Based on the rates of VTE from our retrospective treatment registry analysis 
      compared to the risk of medication-induced haemorrhage, routine prophylactic 
      anticoagulation is not recommended for intra-articular knee BMC procedures. 
      Further research into safety and efficacy of BMC treatment for knee OA is 
      warranted. CLINICAL TRIAL IDENTIFIER: NCT03011398, retrospectively registered.
CI  - (c) 2022. The Author(s).
FAU - Centeno, Christopher J
AU  - Centeno CJ
AD  - Centeno-Schultz Clinic, Broomfield, CO, USA.
AD  - Regenexx, LLC, Research and Development, Broomfield, CO, USA.
FAU - Money, Brandon T
AU  - Money BT
AD  - Centeno-Schultz Clinic, Broomfield, CO, USA.
FAU - Dodson, Ehren
AU  - Dodson E
AUID- ORCID: 0000-0002-5808-6068
AD  - Regenexx, LLC, Research and Development, Broomfield, CO, USA. 
      edodson@regenexx.com.
FAU - Stemper, Ian
AU  - Stemper I
AD  - Regenexx, LLC, Research and Development, Broomfield, CO, USA.
FAU - Steinmetz, Neven J
AU  - Steinmetz NJ
AD  - Regenexx, LLC, Research and Development, Broomfield, CO, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03011398
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220718
PL  - Germany
TA  - Int Orthop
JT  - International orthopaedics
JID - 7705431
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - *Bone Marrow
MH  - Humans
MH  - *Osteoarthritis, Knee/therapy
MH  - Retrospective Studies
MH  - *Venous Thromboembolism/epidemiology/prevention & control
PMC - PMC9492566
OTO - NOTNLM
OT  - Bone marrow concentrate (BMC)
OT  - Deep vein thrombosis (DVT)
OT  - Knee osteoarthritis (OA)
OT  - Pulmonary embolism (PE)
OT  - Total knee arthroplasty (TKA)
OT  - Venous thromboembolism (VTE)
COIS- One or more of the authors has declared a potential conflict of interest. ED, IS, 
      and NJS are employed by Regenexx, LLC. CJC is a shareholder, patent holder, and 
      Chief Medical Officer of Regenexx, LLC, and an owner of the Centeno-Schultz 
      Clinic. BTM is employed by the Centeno-Schultz Clinic.
EDAT- 2022/07/18 06:00
MHDA- 2022/09/24 06:00
PMCR- 2022/07/18
CRDT- 2022/07/17 23:19
PHST- 2022/04/01 00:00 [received]
PHST- 2022/06/23 00:00 [accepted]
PHST- 2022/07/18 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/07/17 23:19 [entrez]
PHST- 2022/07/18 00:00 [pmc-release]
AID - 10.1007/s00264-022-05500-3 [pii]
AID - 5500 [pii]
AID - 10.1007/s00264-022-05500-3 [doi]
PST - ppublish
SO  - Int Orthop. 2022 Oct;46(10):2213-2218. doi: 10.1007/s00264-022-05500-3. Epub 2022 
      Jul 18.